CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Atogepant is an oral CGRP receptor antagonist (gepant) in development for the prevention of migraine. Results of a Phase 2b/3 study and the Phase 3 ADVANCE trial will form the basis of regulatory submissions for atogepant in migraine prevention in adults.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
